Mass torts and MDLs, explained

A mass tort is not a class action

People use the terms interchangeably and they are structurally different, in a way that affects what you get.

In a class action, one representative litigates on behalf of everyone in the class, and the outcome binds all of them. Individual damages are usually similar and often modest.

In a mass tort, each injured person keeps their own individual lawsuit. The cases are grouped for efficiency, most often as a federal multidistrict litigation (MDL) under 28 U.S.C. § 1407, where the Judicial Panel on Multidistrict Litigation transfers related cases to one judge for pretrial proceedings. Discovery and general causation get decided once rather than a thousand times. Your case stays yours, and your recovery depends on your own facts and injuries.

Bellwether trials, and why settlements take years

An MDL judge typically selects a small number of representative cases to try first. These bellwethers are not binding on anyone else, but the verdicts tell both sides what juries do with the evidence, and that is usually what makes global resolution possible.

This is also why mass torts move slowly. An MDL can run for years before the first bellwether, and the gap between a case being filed and anything happening can feel like nothing is happening. Often nothing visible is.

What generally determines whether someone can participate

Every litigation sets its own criteria and they change as the litigation develops. The recurring elements are:

• Product identification. Proof you used or were exposed to the specific product, often the specific manufacturer, and sometimes a particular lot or model. Pharmacy records, purchase history and medical records do this work. This is the most common reason a claim fails at the door.
• A diagnosed injury on the list. Litigations are defined around specific diagnoses, not general ill health, and the list narrows over time.
• Timing. Exposure before or after a particular date, a minimum duration of use, and a plausible latency between exposure and diagnosis.
• The limitation period. Individual statutes of limitation still apply, and the discovery rule (when you knew or should have known the injury was connected to the product) is frequently the battleground.
• Records. Almost all of this is proved with documents. People who start gathering medical and pharmacy records early are in a materially better position.

The advertising you have probably seen

Mass tort advertising is heavily funded and relentless, and some of it is misleading in ways worth naming. Watch for advertisements that imply a settlement already exists when only a filing has happened; that quote an average recovery, which tells you nothing about your own case and is often drawn from a handful of outliers; that urge you to call immediately about a deadline without saying what deadline; or that do not identify which firm you will actually reach.

None of that means the underlying litigation is not real or that you should not look into it. It means the advertisement is not the place to learn about it.

What we can and cannot do here

We can explain how MDLs work, what bellwethers are, and what kinds of proof these cases turn on. We cannot tell you whether a particular litigation is accepting claims like yours, whether you qualify, or whether your deadline has passed. Those require applying current litigation criteria to your facts, which is legal work.

If you took a medication or used a product and have since been diagnosed with something you think may be connected, the useful next step is to gather your records and speak to a lawyer who handles that specific litigation.